207 related articles for article (PubMed ID: 22159452)
1. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient.
Van Nuffel AM; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
Cancer Immunol Immunother; 2012 Jul; 61(7):1033-43. PubMed ID: 22159452
[TBL] [Abstract][Full Text] [Related]
2. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
[TBL] [Abstract][Full Text] [Related]
4. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients.
Wilgenhof S; Van Nuffel AMT; Benteyn D; Corthals J; Aerts C; Heirman C; Van Riet I; Bonehill A; Thielemans K; Neyns B
Ann Oncol; 2013 Oct; 24(10):2686-2693. PubMed ID: 23904461
[TBL] [Abstract][Full Text] [Related]
5. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.
Jansen Y; Kruse V; Corthals J; Schats K; van Dam PJ; Seremet T; Heirman C; Brochez L; Kockx M; Thielemans K; Neyns B
Cancer Immunol Immunother; 2020 Dec; 69(12):2589-2598. PubMed ID: 32591862
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases.
Wilgenhof S; Corthals J; Van Nuffel AM; Benteyn D; Heirman C; Bonehill A; Thielemans K; Neyns B
Cancer Immunol Immunother; 2015 Mar; 64(3):381-8. PubMed ID: 25548092
[TBL] [Abstract][Full Text] [Related]
8. mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70).
Coosemans A; Tuyaerts S; Morias K; Corthals J; Heirman C; Thielemans K; Van Gool SW; Vergote I; Amant F
Methods Mol Biol; 2016; 1428():277-83. PubMed ID: 27236806
[TBL] [Abstract][Full Text] [Related]
9. Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70.
Pen JJ; De Keersmaecker B; Maenhout SK; Van Nuffel AM; Heirman C; Corthals J; Escors D; Bonehill A; Thielemans K; Breckpot K; Aerts JL
J Immunol; 2013 Aug; 191(4):1976-83. PubMed ID: 23842750
[TBL] [Abstract][Full Text] [Related]
10. Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a TriMix of costimulatory molecules.
Benteyn D; Van Nuffel AM; Wilgenhof S; Bonehill A
Methods Mol Biol; 2014; 1139():3-15. PubMed ID: 24619665
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy.
Van Lint S; Goyvaerts C; Maenhout S; Goethals L; Disy A; Benteyn D; Pen J; Bonehill A; Heirman C; Breckpot K; Thielemans K
Cancer Res; 2012 Apr; 72(7):1661-71. PubMed ID: 22337996
[TBL] [Abstract][Full Text] [Related]
13. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.
Schuurhuis DH; Verdijk P; Schreibelt G; Aarntzen EH; Scharenborg N; de Boer A; van de Rakt MW; Kerkhoff M; Gerritsen MJ; Eijckeler F; Bonenkamp JJ; Blokx W; van Krieken JH; Boerman OC; Oyen WJ; Punt CJ; Figdor CG; Adema GJ; de Vries IJ
Cancer Res; 2009 Apr; 69(7):2927-34. PubMed ID: 19318559
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.
Van Nuffel AM; Benteyn D; Wilgenhof S; Pierret L; Corthals J; Heirman C; van der Bruggen P; Coulie PG; Neyns B; Thielemans K; Bonehill A
Mol Ther; 2012 May; 20(5):1063-74. PubMed ID: 22371843
[TBL] [Abstract][Full Text] [Related]
15. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
[TBL] [Abstract][Full Text] [Related]
17. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.
de Jong W; Aerts J; Allard S; Brander C; Buyze J; Florence E; van Gorp E; Vanham G; Leal L; Mothe B; Thielemans K; Plana M; Garcia F; Gruters R;
Trials; 2019 Jun; 20(1):361. PubMed ID: 31208472
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA.
Bonehill A; Tuyaerts S; Van Nuffel AM; Heirman C; Bos TJ; Fostier K; Neyns B; Thielemans K
Mol Ther; 2008 Jun; 16(6):1170-80. PubMed ID: 18431362
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells.
Van Lint S; Renmans D; Broos K; Goethals L; Maenhout S; Benteyn D; Goyvaerts C; Du Four S; Van der Jeught K; Bialkowski L; Flamand V; Heirman C; Thielemans K; Breckpot K
Cancer Immunol Res; 2016 Feb; 4(2):146-56. PubMed ID: 26659303
[TBL] [Abstract][Full Text] [Related]
20. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]